Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Aug 16;23(1):780.
doi: 10.1186/s12891-022-05739-2.

Prevention of muscle atrophy in ICU patients without nerve injury by neuromuscular electrical stimulation: a randomized controlled study

Weiwei Bao  1 , Jiajia Yang  2 , Mingna Li  3 , Kang Chen  1 , Zheng Ma  1 , Yuehong Bai  1 , Yiming Xu  4
Affiliations
Randomized Controlled Trial

Prevention of muscle atrophy in ICU patients without nerve injury by neuromuscular electrical stimulation: a randomized controlled study

Weiwei Bao et al. BMC Musculoskelet Disord. .

Abstract

Background: Extensive muscle atrophy is a common occurrence in orthopaedics patients who are bedridden or immobilized. The incidence is higher in intensive care unit (ICU) inpatients. There is still controversy about how to use neuromuscular electrical stimulation (NMES) in ICU patients. We aim to compare the effectiveness and safety of NMES to prevent muscle atrophy in intensive care unit (ICU) patients without nerve injury.

Methods: ICU patients without central and peripheral nerve injury were randomized into experimental group I (Exp I: active and passive activity training (APAT) + NMES treatment on the gastrocnemius and tibialis anterior muscle), experimental group II (Exp II: APAT + NMES treatment on gastrocnemius alone), and control group (Ctl: APAT alone). Changes in the strength of gastrocnemius, the ankle range of motion, and the muscle cross-section area of the lower leg were evaluated before and after the intervention. Also, changes in prothrombin time, lactic acid, and C-reactive protein were monitored during the treatment.

Results: The gastrocnemius muscle strength, ankle joint range of motion, and cross-sectional muscle area of the lower leg in the three groups showed a downward trend, indicating that the overall trend of muscle atrophy in ICU patients was irreversible. The decrease in gastrocnemius muscle strength in Exp I and Exp II was smaller than that in the control group (P < 0.05), but there was no difference between Exp I and Exp II. The decrease in active ankle range of motion and cross-sectional area of the lower leg Exp I and Exp II was smaller than that in the control group (P < 0.05), and the decrease in Exp I was smaller than that of Exp II (all P < 0.05). The curative effect in Exp I was better than in Exp II. There were no significant differences in the dynamic changes of prothrombin time, lactic acid, and C-reactive protein during the three groups (P > 0.05).

Conclusion: In addition to early exercise training, NMES should be applied to prevent muscle atrophy for patients without nerve injury in ICU. Also, simultaneous NMES treatment on agonist/antagonist muscle can enhance the effect of preventing muscle atrophy.

Trial registration: This study was prospectively registered in China Clinical Trial Registry ( www.chictr.org.cn ) on 16/05/2020 as ChiCTR2000032950.

Keywords: Efficacy; ICU; Muscular atrophy; NMES; Prevention; Safety; Strategy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the study
Fig. 2
Fig. 2
Neuromuscular electrical stimulation treatment. a NMES on the gastrocnemius and tibialis anterior muscles in experimental group I . b NMES on gastrocnemius alone in experimental group II
Fig. 3
Fig. 3
Measure the strength of gastrocnemius muscle (a) and Active joint range of motion of ankle joint (b)
Fig. 4
Fig. 4
Lower leg CT plain scan and muscle area marking. a CT cross-section image of the lower leg (10 cm below the tibial tubercle). b Muscle boundary was marked with ImageJ; the cross-sectional area of the muscle was automatically calculated
Fig. 5
Fig. 5
Comparison of gastrocnemius muscle strength before and after treatment. a Decrease of gastrocnemius muscle strength before and after treatment in the three groups. b Gastrocnemius muscle strength gap before and after treatment among the three groups. Exp I: experimental group I, Exp II: experimental group II, Ctl: control group; Bef: before treatment, Aft: after treatment; * P < 0.05 between each group before and after treatment; # P < 0.05 vs. control group
Fig. 6
Fig. 6
Comparison of AROM of ankle joint before and after treatment. a AROM of ankle joint before and after treatment among three groups. b Comparison of ankle AROM gap before and after treatment in three groups. Exp I: experimental group I, Exp II: experimental group II, Ctl: control group; Bef: before treatment, Aft: after treatment; * P < 0.05 between each group before and after treatment; # P < 0.05 vs. control group; & P < 0.05 between the Exp I and the Exp II
Fig. 7
Fig. 7
Comparison of muscle CSA of the lower leg before and after treatment. a Decrease of muscle CSA of the lower leg before and after treatment among three groups. b Comparison of muscle CSA gap before and after treatment in three groups. Exp I: experimental group I, Exp II: experimental group II, Ctl: control group; Bef: before treatment, Aft: after treatment; CSA: cross-sectional area; * P < 0.05 between each group before and after treatment; # P < 0.05 vs. Ctl; & P < 0.05 between Exp I and the Exp II
Fig. 8
Fig. 8
Comparison of the changes of CRP (a), lactic acid (b), and PT (c) in the three groups during treatment. Exp I: experimental group I, Exp II: experimental group II, Ctl: control group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wall BT, Dirks ML, van Loon LJC. Skeletal muscle atrophy during short-term disuse: implications for age-related sarcopenia. Ageing Res Rev. 2013;12(4):898–906. doi: 10.1016/j.arr.2013.07.003. - DOI - PubMed
    1. Memme JM, Slavin M, Moradi N, Hood DA. Mitochondrial bioenergetics and turnover during chronic muscle disuse. Int J Mol Sci. 2021;22(10):5179. doi: 10.3390/ijms22105179. - DOI - PMC - PubMed
    1. Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. Intensive Care Med. 2020;46(4):637–653. doi: 10.1007/s00134-020-05944-4. - DOI - PMC - PubMed
    1. Tortuyaux R, Davion JB, Jourdain M. Intensive care unit-acquired weakness: questions the clinician should ask. Rev Neurol (Paris) 2022;178(1–2):84–92. doi: 10.1016/j.neurol.2021.12.007. - DOI - PubMed
    1. Sousa AS, Guerra RS, Fonseca I, Pichel F, Amaral TF. Sarcopenia among hospitalized patients - a cross-sectional study. Clin Nutr. 2015;34(6):1239–1244. doi: 10.1016/j.clnu.2014.12.015. - DOI - PubMed

Publication types

-